SI1341533T1 - Sinergisticne kombinacije vsebujoce reninski inhibitor za kardiovaskularne bolezni - Google Patents

Sinergisticne kombinacije vsebujoce reninski inhibitor za kardiovaskularne bolezni

Info

Publication number
SI1341533T1
SI1341533T1 SI200130530T SI200130530T SI1341533T1 SI 1341533 T1 SI1341533 T1 SI 1341533T1 SI 200130530 T SI200130530 T SI 200130530T SI 200130530 T SI200130530 T SI 200130530T SI 1341533 T1 SI1341533 T1 SI 1341533T1
Authority
SI
Slovenia
Prior art keywords
renin inhibitor
cardiovascular diseases
synergistic combinations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
SI200130530T
Other languages
English (en)
Slovenian (sl)
Inventor
William Hewitt
Daniel Lucius Vasella
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1341533(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1341533T1 publication Critical patent/SI1341533T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
SI200130530T 2000-11-17 2001-11-15 Sinergisticne kombinacije vsebujoce reninski inhibitor za kardiovaskularne bolezni SI1341533T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds
PCT/EP2001/013241 WO2002040007A1 (en) 2000-11-17 2001-11-15 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Publications (1)

Publication Number Publication Date
SI1341533T1 true SI1341533T1 (sl) 2006-08-31

Family

ID=9903412

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200130530T SI1341533T1 (sl) 2000-11-17 2001-11-15 Sinergisticne kombinacije vsebujoce reninski inhibitor za kardiovaskularne bolezni
SI200131026T SI1915993T1 (sl) 2000-11-17 2001-11-15 Sinergistične kombinacije, ki obsegajo reninski inhibitor, za kardiovaskularne bolezni
SI200130850T SI1602370T1 (sl) 2000-11-17 2001-11-15 Sinergistične kombinacuje, ki vsebujejo reninskiinhibitor, za kardiovaskularne bolezni

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200131026T SI1915993T1 (sl) 2000-11-17 2001-11-15 Sinergistične kombinacije, ki obsegajo reninski inhibitor, za kardiovaskularne bolezni
SI200130850T SI1602370T1 (sl) 2000-11-17 2001-11-15 Sinergistične kombinacuje, ki vsebujejo reninskiinhibitor, za kardiovaskularne bolezni

Country Status (31)

Country Link
US (4) US8168616B1 (enExample)
EP (7) EP1602370B1 (enExample)
JP (6) JP2004513920A (enExample)
KR (6) KR20100114904A (enExample)
CN (4) CN101264072A (enExample)
AT (2) ATE317692T1 (enExample)
AU (2) AU2002223680B2 (enExample)
BR (1) BR0115411A (enExample)
CA (2) CA2763223A1 (enExample)
CY (5) CY1105603T1 (enExample)
CZ (2) CZ305341B6 (enExample)
DE (3) DE122009000021I1 (enExample)
DK (3) DK1341533T3 (enExample)
EC (1) ECSP034603A (enExample)
ES (4) ES2734523T3 (enExample)
GB (1) GB0028151D0 (enExample)
HU (2) HU230882B1 (enExample)
IL (3) IL155707A (enExample)
LU (2) LU91563I2 (enExample)
MX (1) MXPA03004358A (enExample)
NL (2) NL300385I1 (enExample)
NO (2) NO334002B1 (enExample)
NZ (6) NZ525795A (enExample)
PL (3) PL227576B1 (enExample)
PT (3) PT1341533E (enExample)
RU (2) RU2310443C2 (enExample)
SG (1) SG135969A1 (enExample)
SI (3) SI1341533T1 (enExample)
SK (1) SK287881B6 (enExample)
WO (1) WO2002040007A1 (enExample)
ZA (1) ZA200303497B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
PL219032B1 (pl) * 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
US20050147629A1 (en) * 2002-06-28 2005-07-07 Jutta Riedl Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
US7582782B2 (en) * 2003-11-26 2009-09-01 Novartis Ag Organic compounds
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CN1910136A (zh) * 2004-01-23 2007-02-07 斯皮德尔实验股份公司 有机化合物
ES2348016T3 (es) * 2004-01-23 2010-11-26 Novartis Ag Diamino alcoholoes y su uso como inhibidores de la renina.
DE602005025344D1 (de) * 2004-01-23 2011-01-27 Novartis Ag Aminoalkoholderivate und deren wirkung als renininhibitoren
CA2558020A1 (en) * 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
EP1725530A1 (en) * 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
RU2407523C2 (ru) * 2004-10-08 2010-12-27 Новартис Аг Применение ингибиторов ренина для профилактики или лечения диастолической дисфункции или диастолической сердечной недостаточности
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
JP2008539250A (ja) * 2005-04-27 2008-11-13 ノバルティス アクチエンゲゼルシャフト アテローム性動脈硬化症を処置するための方法
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
ES2303198T3 (es) * 2005-09-28 2008-08-01 Teva Pharmaceutical Industries Ltd. Combinaciones estables de besilato de amlodipina e hidrocloruro de benazeprilo.
WO2007056324A2 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN101404981A (zh) * 2006-03-13 2009-04-08 恩希赛弗制药公司 治疗舒张性心力衰竭的方法和组合物
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
US20100029775A1 (en) * 2006-12-15 2010-02-04 Prescott Margaret F Renin inhibitors for the prevention and treatment of hypertension in obese patients
US20080194626A1 (en) * 2007-02-14 2008-08-14 Gorczynski Richard J Antihypertensive drug combination
JP2010540547A (ja) * 2007-09-28 2010-12-24 ノバルティス アーゲー アリスキレンおよびバルサルタンのガレヌス製剤
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
US20110111021A1 (en) 2008-02-22 2011-05-12 Hanall Biopharma Co., Ltd. Pharmaceutical preparation
EP2275093A2 (en) 2008-04-10 2011-01-19 HanAll Biopharma Co., Ltd. Pharmaceutical formulation
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
EP2281557A4 (en) 2008-04-29 2011-08-31 Hanall Biopharma Co Ltd PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
CN102348452A (zh) 2009-03-20 2012-02-08 诺瓦提斯公司 缬沙坦和阿利吉仑的固定剂量组合的盖仑制剂
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2704706A1 (en) 2011-05-06 2014-03-12 Artskin D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
SG11201407200TA (en) * 2012-05-18 2014-12-30 Luoda Pharma Pty Ltd Liquid formulation
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
AU2015295845B2 (en) 2014-07-30 2020-03-05 Merck Patent Gmbh Directly compressible polyvinyl alcohols
CN109890389B (zh) * 2016-10-27 2022-07-01 达米安制药股份公司 醛固酮合酶抑制剂

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
ATE250587T1 (de) 1989-06-14 2003-10-15 Smithkline Beecham Corp Imidazoalkensäure
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
EP0527879B1 (en) 1990-05-11 1997-02-05 Pfizer Inc. Synergistic therapeutic compositions and methods
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
WO1992003429A1 (en) * 1990-08-15 1992-03-05 Abbott Laboratories Renin inhibitors
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
ES2130170T3 (es) * 1990-12-14 1999-07-01 Smithkline Beecham Corp Composiciones bloqueantes del receptor de la angiotensina ii.
EP0498361A3 (en) 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
CA2061607C (en) 1991-02-21 1999-01-19 Hiroaki Yanagisawa 1-biphenylimidazole derivatives, their preparation and their therapeutic use
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (enExample) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
MA23172A1 (fr) 1993-04-27 1994-12-31 Smithkline Beecham Corp Antagonistes de recepteurs d'endotheline .
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
DE59409631D1 (de) * 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
DE69426698T2 (de) 1993-08-18 2001-08-16 Banyu Pharmaceutical Co., Ltd. Kondensierte heteroaromatische cyclopentenderivate mit endothelin-antagonistischer aktivität
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
DE69527072T2 (de) 1994-08-19 2003-02-13 Abbott Laboratories, Abbott Park Endothelin antagoniste
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
KR19980701690A (ko) 1995-01-27 1998-06-25 리 카핀 엔도텔린 길항제로서의 치환 페닐 화합물
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
AU703386B2 (en) 1995-12-20 1999-03-25 Astellas Pharma Inc. Arylethenesulfonamide derivatives and drug composition containing the same
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
ES2241047T3 (es) 1996-04-04 2005-10-16 Banyu Pharmaceutical Co., Ltd. Antagonistas de la endotelina para tratar la insuficiencia cardiaca.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
JP4575594B2 (ja) 1998-07-20 2010-11-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 経口用固体剤形のエプロサルタン配合の生体内強化性処方
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
WO2000056403A1 (en) * 1999-03-19 2000-09-28 The Brigham And Women's Hospital, Inc. UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
DE60036122T2 (de) 1999-11-09 2008-05-15 Pharmacia Corp. Verwendung von eplerenon zur behandlung von restenose
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
PL219032B1 (pl) 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
DE50309932D1 (de) 2002-12-31 2008-07-10 Volkswagen Ag Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine

Also Published As

Publication number Publication date
CZ305341B6 (cs) 2015-08-05
NL300385I1 (nl) 2009-07-01
NO334002B1 (no) 2013-11-11
KR101258365B1 (ko) 2013-04-30
BR0115411A (pt) 2004-08-17
ES2734523T3 (es) 2019-12-10
ZA200303497B (en) 2004-04-28
NL301005I2 (nl) 2019-10-29
RU2310443C2 (ru) 2007-11-20
NL301005I1 (enExample) 2019-09-10
CN101091703A (zh) 2007-12-26
NZ550897A (en) 2008-03-28
AU2002223680B2 (en) 2005-04-07
CY2013045I1 (el) 2015-11-04
NZ550898A (en) 2008-07-31
EP1602370B1 (en) 2008-06-04
HK1089356A1 (en) 2006-12-01
SI1602370T1 (sl) 2008-10-31
EP2305232A1 (en) 2011-04-06
US8168616B1 (en) 2012-05-01
EP1915993B1 (en) 2013-07-10
JP6089278B2 (ja) 2017-03-08
PL361404A1 (en) 2004-10-04
EP1930000A1 (en) 2008-06-11
KR20030051753A (ko) 2003-06-25
KR20080011355A (ko) 2008-02-01
JP2009235107A (ja) 2009-10-15
ES2256335T3 (es) 2006-07-16
NO20032233D0 (no) 2003-05-16
DK1341533T3 (da) 2006-05-08
CN1474690A (zh) 2004-02-11
SG135969A1 (en) 2007-10-29
CY2013045I2 (el) 2015-11-04
PL227576B1 (pl) 2017-12-29
JP2004513920A (ja) 2004-05-13
DE60117295D1 (de) 2006-04-20
DE122009000021I1 (de) 2009-08-06
HK1059212A1 (en) 2004-06-25
PL400914A1 (pl) 2012-12-17
ECSP034603A (es) 2003-06-25
US20120010295A1 (en) 2012-01-12
JP6603757B2 (ja) 2019-11-06
MXPA03004358A (es) 2003-08-19
IL155707A (en) 2012-02-29
KR101008752B1 (ko) 2011-01-14
EP1341533B1 (en) 2006-02-15
RU2006132668A (ru) 2008-03-20
CN101264073A (zh) 2008-09-17
HK1115544A1 (en) 2008-12-05
JP6577994B2 (ja) 2019-09-18
RU2346703C2 (ru) 2009-02-20
NZ525795A (en) 2005-03-24
DK1915993T3 (da) 2013-10-14
ES2308347T3 (es) 2008-12-01
EP1915993A1 (en) 2008-04-30
SK5842003A3 (en) 2003-11-04
NO2013019I1 (no) 2014-06-02
SK287881B6 (sk) 2012-02-03
EP1602370A3 (en) 2005-12-14
US20120004312A1 (en) 2012-01-05
EP1341533A1 (en) 2003-09-10
CY1105603T1 (el) 2010-07-28
AU2368002A (en) 2002-05-27
DE60134349D1 (de) 2008-07-17
ATE397445T1 (de) 2008-06-15
JP2013213061A (ja) 2013-10-17
JP2017019876A (ja) 2017-01-26
CZ299749B6 (cs) 2008-11-12
CY2009005I1 (el) 2012-01-25
KR20110063596A (ko) 2011-06-10
CY1108305T1 (el) 2012-01-25
HU1400409D0 (hu) 2003-09-29
PT1602370E (pt) 2008-09-10
EP1602370A2 (en) 2005-12-07
JP2018030894A (ja) 2018-03-01
US9023894B2 (en) 2015-05-05
HUP0301841A3 (en) 2010-07-28
NZ568764A (en) 2009-11-27
WO2002040007A1 (en) 2002-05-23
SI1915993T1 (sl) 2013-10-30
US20120016035A1 (en) 2012-01-19
PT1341533E (pt) 2006-06-30
NO20032233L (no) 2003-05-16
CY2009005I2 (el) 2012-01-25
PL400915A1 (pl) 2012-12-17
HUP0301841A2 (hu) 2003-09-29
US9023893B2 (en) 2015-05-05
DK1602370T3 (da) 2008-09-22
DE60117295T2 (de) 2006-08-17
JP2018131465A (ja) 2018-08-23
KR20080096715A (ko) 2008-10-31
EP2305231A1 (en) 2011-04-06
LU92315I2 (fr) 2014-01-27
IL212075A0 (en) 2011-06-30
KR20080097488A (ko) 2008-11-05
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
IL155707A0 (en) 2003-11-23
CA2428647A1 (en) 2002-05-23
IL212075A (en) 2013-08-29
LU91563I2 (fr) 2009-07-06
CY1114829T1 (el) 2015-11-04
KR20100114904A (ko) 2010-10-26
CN100404024C (zh) 2008-07-23
ES2429292T3 (es) 2013-11-14
GB0028151D0 (en) 2001-01-03
US8618174B2 (en) 2013-12-31
JP6373931B2 (ja) 2018-08-15
HU230882B1 (hu) 2018-11-29
CN101264072A (zh) 2008-09-17
EP2305232B1 (en) 2019-07-17
NO2013019I2 (no) 2013-12-17
CA2763223A1 (en) 2002-05-23
ATE317692T1 (de) 2006-03-15
IL217847A0 (en) 2012-03-29
EP2305233A1 (en) 2011-04-06
NZ537691A (en) 2007-01-26

Similar Documents

Publication Publication Date Title
NL301005I1 (enExample)
HUP0102281A3 (en) Prodrugs of dipeptidyl peptidase iv inhibitors, pharmaceutical compositions comprising thereof and their use
IL148630A0 (en) Compounds and pharmaceutical compositions for inhibiting cathepsin s
HUP9601566A2 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
BG106586A (en) Pyrazolopyramidines as therapeutic agents
HUP0200881A2 (en) Renin inhibitors, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
CA2386793A1 (en) New selective retinoid agonists
GB9907571D0 (en) Compounds
EP0870502A3 (en) Use of adenosine uptake inhibitors for the manufacture of a medicament for the treatment of pancreatitis
EP0978287A4 (en) MEDICAL COMPOSITION CONTAINING AS GP34 INHIBITOR BINDING INHIBITOR.
CA2370501A1 (en) Pharmaceutical composition for the therapy of lower urinary tract symptoms
IL135993A0 (en) Pharmaceutical composition for the treatment of fibrosis
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
IL127227A0 (en) A pharmaceutical composition for the treatment of multiple sclerosis